Stocks and InvestingStocks and Investing
Tue, March 16, 2021
Mon, March 15, 2021
Sun, March 14, 2021
Fri, March 12, 2021
Thu, March 11, 2021
Wed, March 10, 2021
Tue, March 9, 2021

Sumant Kulkarni Maintained (ACAD) at Strong Buy with Decreased Target to $40 on, Mar 9th, 2021


Published on 2024-10-27 15:53:15 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Decreased Target from $61 to $40 on, Mar 9th, 2021.

Sumant has made no other calls on ACAD in the last 4 months.



There is 1 other peer that has a rating on ACAD. Out of the 1 peers that are also analyzing ACAD, 0 agree with Sumant's Rating of Hold.



This is the rating of the analyst that currently disagrees with Sumant


  • Vamil Divan of "Mizuho" Initiated at Strong Buy and Held Target at $69 on, Wednesday, December 16th, 2020